Published in Curr Infect Dis Rep on February 01, 2002
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy. Curr Infect Dis Rep (2004) 0.82
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA (1998) 6.69
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection. HIV Clin Trials (2001) 4.51
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
The Multicenter AIDS Cohort Study: retention after 9 1/2 years. Am J Epidemiol (1995) 3.54
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
Decline in deaths from AIDS due to new antiretrovirals. Lancet (1997) 3.13
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS (2001) 2.85
Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (2001) 2.51
Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol (1990) 2.50
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS (2001) 2.47
Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis (2000) 2.36
Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis (2001) 2.19
Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis (1999) 2.17
Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry (1993) 2.07
HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS (1999) 1.86
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS (2001) 1.79
Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis (2001) 1.76
Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. Clin Infect Dis (1999) 1.58
Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.48
Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol (2000) 1.36
Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (1999) 1.36
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis (1999) 1.32
Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.29
Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. J Clin Invest (1999) 1.19
HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood (2000) 1.14
Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS (1998) 1.12
Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. Arch Intern Med (2000) 1.12
Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol (2002) 1.11
Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS (2000) 1.11
Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr (2001) 1.10
Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS (1999) 1.08
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS (1999) 1.04
Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir Immune Defic Syndr (2001) 1.01
Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS (2000) 1.01
Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. JAMA (1999) 1.01
CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS (2000) 0.91
CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis (1999) 0.91
CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. AIDS (2001) 0.87
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis (2001) 0.87
Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin Infect Dis (2001) 0.85
Therapy naivete in the era of potent antiretroviral therapy. J Clin Epidemiol (2001) 0.84
Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J Acquir Immune Defic Syndr (2001) 0.84
Comparison of T-cell subsets' reconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease. J Acquir Immune Defic Syndr (2000) 0.84
The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study. J Infect Dis (2000) 0.81
Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection. AIDS Res Hum Retroviruses (2001) 0.79
Effects of virologic rebound on CD4 cell counts. Clin Infect Dis (2001) 0.78
Response to highly active antiretroviral therapy according to duration of HIV infection. J Acquir Immune Defic Syndr (2001) 0.78
Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals. HIV Clin Trials (2001) 0.75
Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy. Curr Infect Dis Rep (2004) 0.82